2024
Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis
Murray T, Stanley G, Koff J. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. Infectious Disease Clinics Of North America 2024, 38: 149-162. PMID: 38280761, DOI: 10.1016/j.idc.2023.12.002.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsAnti-Infective AgentsCystic FibrosisHumansMethicillin-Resistant Staphylococcus aureusRespiratory Tract InfectionsStenotrophomonas maltophiliaConceptsMultidrug-resistant organismsCystic fibrosis transmembrane conductance regulatorCystic fibrosisBeta-lactam/beta-lactamase combinationDevelopment of inhaled formulationsMethicillin-resistant Staphylococcus aureusTherapeutic approachesMultidrug-resistant organism infectionSystemic adverse eventsMultidrug-resistant infectionsTransmembrane conductance regulatorRespiratory tract infectionsCystic fibrosis patientsGram-negative organismsInnovative therapeutic approachesPulmonary infectionTract infectionsConductance regulatorBurkholderia sp.Multidrug resistanceAdverse eventsTreatment optionsAntibiotic resistanceFibrosis patientsOptimal dose
2022
Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis
Murray T, Stanley G, Koff J. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. Clinics In Chest Medicine 2022, 43: 667-676. PMID: 36344073, DOI: 10.1016/j.ccm.2022.06.008.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsCystic FibrosisHumansMethicillin-Resistant Staphylococcus aureusPseudomonas aeruginosaPseudomonas InfectionsRespiratory Tract InfectionsStenotrophomonas maltophiliaConceptsMultidrug-resistant organismsCystic fibrosisTherapeutic approachesNontuberculous mycobacteriaCystic fibrosis transmembrane conductance regulator (CFTR) dysfunctionSystemic adverse eventsRespiratory tract infectionsMethicillin-resistant Staphylococcus aureusAdditional clinical trialsNew treatment optionsPharmacokinetics/pharmacodynamicsInnovative therapeutic approachesMultidrug-resistant infectionsMDRO infectionAdverse eventsPulmonary infectionTract infectionsOptimal dosingTreatment optionsClinical trialsNew therapiesNegative organismsInfectionAntibiotic resistancePatients
2012
Rhinovirus and other respiratory viruses exert different effects on lung allograft function that are not mediated through acute rejection
Sayah DM, Koff JL, Leard LE, Hays SR, Golden JA, Singer JP. Rhinovirus and other respiratory viruses exert different effects on lung allograft function that are not mediated through acute rejection. Clinical Transplantation 2012, 27: e64-e71. PMID: 23278569, PMCID: PMC3558613, DOI: 10.1111/ctr.12054.Peer-Reviewed Original ResearchConceptsLung transplant recipientsAcute rejectionAllograft functionCARV infectionBiopsy-proven acute rejectionIncidence of ARLung allograft functionTransbronchial biopsy resultsReference groupChronic allograft rejectionRespiratory virus infectionsAllograft dysfunctionLung allograftsTransplant recipientsAllograft rejectionExpiratory volumePrimary outcomeRespiratory virusesAdverse outcomesClinical recordsRV infectionBaseline incidenceBiopsy resultsMonths postinfectionVirus infection